Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 1,500 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,500 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were bought at an average cost of $15.89 per share, with a total value of $23,835.00. Following the purchase, the chief executive officer now directly owns 5,527,102 shares of the company’s stock, valued at approximately $87,825,650.78. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Snehal Patel also recently made the following trade(s):

• On Thursday, June 13th, Snehal Patel acquired 174,825 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $14.30 per share, for a total transaction of $2,499,997.50.

Greenwich LifeSciences Trading Up 6.9 %

NASDAQ GLSI opened at $16.62 on Friday. The firm’s fifty day simple moving average is $15.24 and its two-hundred day simple moving average is $13.93. Greenwich LifeSciences, Inc. has a 12-month low of $7.58 and a 12-month high of $21.44. The firm has a market capitalization of $214.07 million, a P/E ratio of -23.08 and a beta of 1.64.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings results on Monday, May 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. As a group, sell-side analysts predict that Greenwich LifeSciences, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of Greenwich LifeSciences in a report on Wednesday, May 22nd.

Hedge Funds Weigh In On Greenwich LifeSciences

An institutional investor recently bought a new position in Greenwich LifeSciences stock. Bank of New York Mellon Corp acquired a new stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,295 shares of the company’s stock, valued at approximately $264,000. Bank of New York Mellon Corp owned about 0.12% of Greenwich LifeSciences at the end of the most recent reporting period. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.